FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
Spectral CT System Gets FDA Clearance for Radiation Oncology Use
The Spectral CT 7500 RT system reportedly combines 4D conventional computed tomography (CT) with the enhanced quantification and visualization of spectral CT to facilitate improved precision with radiotherapy.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.